Pradaxa dabigatran etexilate regulatory update

FDA accepted for review an sNDA from Boehringer for Pradaxa dabigatran etexilate to prevent deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have had primary elective total hip...